Subjective Versus Objective Weight Gain During Acute Treatment With Second-Generation Antipsychotics in Schizophrenia and Bipolar Disorder
Authors:
- 1 December 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 36 (6) , 637-642
Abstract
Objectives: To compare objective and subjective weight gain of second-generation antipsychotics in schizophrenia and bipolar disorder. Methods: English-language literature published and cited in PubMed (MEDLINE) from January 1966 to December 2015 was searched with the keywords antipsychotic, atypical antipsychotic, or generic/brand name of atypical antipsychotics, and schizophrenia, bipolar disorder, bipolar mania, or bipolar depression, and safety, tolerability, weight gain, and randomized, placebo-controlled clinical trials. The absolute risk increases and the numbers needed to treat to harm (NNH) for ≥7% weight gain (objective) and self-report weight gain (subjective) were estimated. Results: In schizophrenia, the NNH for 7% or greater weight gain ranged from 5 to 62, and the NNH for self-reported weight gain was from 11 to −224. The ratio of self-reported NNH to 7% or greater NNH was from 1.5 to 8.0. In bipolar mania, the NNH for 7% or greater weight gain ranged from 7 to −101 and the NNH for self-reported weight gain was from 13 to 84. The ratio of self-reported NNH to 7% or greater NNH was from 0.9 to 2.5. In bipolar depression, the NNH for 7% or greater weight gain ranged from 5 to 69, and the NNH for self-reported weight gain was from 8 to 17. The ratio of self-reported NNH to 7% or greater NNH was 1.2 to 1.6. Conclusions: Subjective reporting underestimated the risk of antipsychotic-related weight gain compared with objectively measured weight change. Self-awareness of antipsychotic-related weight gain was lower in patients with schizophrenia than in patients with bipolar disorder. Measuring weight change during antipsychotic treatment should be a routine practice.Keywords
This publication has 31 references indexed in Scilit:
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisThe Lancet, 2013
- Antipsychotic Drugs Opposite to Metabolic Risk: Neurotransmitters, Neurohormonal and Pharmacogenetic Mechanisms Underlying with Weight Gain and Metabolic SyndromeThe Open Neurology Journal, 2013
- Is the Prevalence of Metabolic Syndrome and Metabolic Abnormalities Increased in Early Schizophrenia? A Comparative Meta-Analysis of First Episode, Untreated and Treated PatientsSchizophrenia Bulletin, 2012
- Accuracy and reliability of self-reported weight and height in the Sister StudyPublic Health Nutrition, 2011
- Association of Psychiatric Illness and Obesity, Physical Inactivity, and Smoking among a National Sample of VeteransPsychosomatics, 2011
- Number Needed to Treat to Harm for Discontinuation Due to Adverse Events in the Treatment of Bipolar Depression, Major Depressive Disorder, and Generalized Anxiety Disorder With Atypical AntipsychoticsThe Journal of Clinical Psychiatry, 2010
- Validity of Self-Reported Weight and Height of Adolescents, Its Impact on Classification into BMI-Categories and the Association with Weighing BehaviourInternational Journal of Environmental Research and Public Health, 2009
- Antipsychotic-Induced Extrapyramidal Side Effects in Bipolar Disorder and SchizophreniaJournal of Clinical Psychopharmacology, 2008
- Accuracy of body image perception and preferred weight loss strategies in schizophrenia: a controlled pilot studyActa Psychiatrica Scandinavica, 2007
- Second-Generation Antipsychotic Exposure and Metabolic-Related Disorders in Patients With SchizophreniaJournal of Clinical Psychopharmacology, 2007